Company & Sponsor Intelligence

AbbVie

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials26

Recruiting6

Completed18

Countries5

Therapeutic footprint

alzheimersautismbipolar_disorderdepressionepilepsymigraine_headachemovement_disordersparkinsonsschizophrenia

Indexed studies

NCT04379050Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
parkinsons · United StatesPHASE3

NCT05125302Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
migraine_headache · United StatesPHASE3

NCT04578756Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
autism · United StatesPHASE3

NCT05291234A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT04244175A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
epilepsy · United StatesPHASE2

NCT06406348A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
alzheimers · United StatesPHASE1

NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
migraine_headache · United StatesACTIVE_NOT_RECRUITING

NCT02906488Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
parkinsons · JapanCOMPLETED

NCT05956483Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting
depression · United StatesCOMPLETED

NCT05916157An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
parkinsons · JapanACTIVE_NOT_RECRUITING

NCT02573740Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
alzheimers · United StatesPHASE1

NCT06605599Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
bipolar_disorder · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →